Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479006 | 0.97 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479698 | 0.94 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479795 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479791 | 0.90 | KDM4E (0.42) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479697 | 0.88 | MAPK1 (0.38) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479705 | 0.87 | HSD17B10 (0.42) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479057 | 0.86 | PARP3 (0.46) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479741 | 0.83 | KDM4E (0.38) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479324 | 0.79 | TSHR (0.38) | SMN1; SMN2KDM4EHPGDMAPK1HSD17B10 | |
| SCHEMBL17479726 | 0.77 | TSHR (0.41) | SMN1; SMN2MAPK1HSD17B10CACNA1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | claimed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | claimed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | claimed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | claimed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-06-04 | — | — | US | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | SMN1; SMN2 3517/4885KDM4E 2965/4885HPGD 3601/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | SMN1; SMN2 3517/4885KDM4E 2965/4885HPGD 3601/4885 |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | FLT3, CSF1R, OPRL1 | SMN1; SMN2 3037/4885KDM4E 362/4885HPGD 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.